publications-banner

Information about pipeline products

PublicationView

T-DXd
Breast Cancer Colorectal Cancer Gastric Cancer Lung Cancer Other/Multi
Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies
Powell CA, Modi S, Iwata H, et al.
ESMO Open. 2022;7(4):100554.
T-DXd
Breast Cancer
Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer.
Modi S, Jacot W, Yamashita T, et al.
N Engl J Med. 2022;387(1):9-20.
T-DXd
Breast Cancer
Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer
Cortes J, Kim SB, Chung WP, et al.
N Engl J Med. 2022;386(12):1143-1154.
Pexidartinib
Other/Multi
Results from phase I extension study assessing pexidartinib treatment in six cohorts with solid tumors including TGCT, and abnormal CSF1 transcripts in TGCT
Tap WD, Singh AS, Anthony SP, et al.
Clin Cancer Res. 2022;28(2):298-307.
HER3-DXd
Lung Cancer
Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated non-small cell lung cancer
Janne PA, Baik C, Su WC, et al.
Cancer Discov. 2022;12(1):74-89.
Edoxaban
Cardiovascular - VTE
One-year incidence of venous thromboembolism, bleeding, and death in patients with solid tumors newly initiating cancer treatment: Results from the Cancer-VTE registry
Ohashi Y, Ikeda M, Kunitoh H, et al.
Thromb Res. 2022;213:P203-213.
T-DXd
Lung Cancer
Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer
Li BT, Smit EF, Goto Y, et al.
N Engl J Med. 2022;386(3):241-251.
Edoxaban
Cardiovascular - AF
Edoxaban versus vitamin K antagonist for atrial fibrillation after TAVR
Van Mieghem NM, Unverdorben M, Hengstenberg C, et al.
N Engl J Med. 2021;385(23):2150-2160.
T-DXd
Breast Cancer
Trastuzumab deruxtecan in previously treated HER2-positive metastatic breast cancer: Plain language summary of the DESTINY-Breast01 study
Modi S.
Future Oncol. 2021;17(26):3415-3423.
Pexidartinib
Other/Multi
Pexidartinib improves physical functioning and stiffness in patients with tenosynovial giant cell tumor: Results from the ENLIVEN randomized clinical trial
van de Sande M, Tap WD, Gelhorn HL, et al.
Acta Orthop. 2021;92(4):493-499.
Pages: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  

footer